MedTrace Logo

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

NCT00300716 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2019-10-15

No results posted yet for this study

Summary

This study is designed to determine whether memantine is an effective treatment for memory and cognitive problems associated with multiple sclerosis when compared to placebo.

Conditions

Interventions

DRUG

Memantine

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • University of Southern California

    collaborator OTHER

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • MS-Hub Seattle

    collaborator UNKNOWN

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Dennis Bourdette, MD · Oregon Health and Science University

  • Lovera Jesus, MD · Oregon Health and Science University

  • Daniel Bandari, MD · University of Southern California

  • Ted Brown, MD · MS Hub

  • Elliot Frohman, MD · UT Southwestern

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300716 on ClinicalTrials.gov